Bio-Gene Technology Limited (ASX:BGT)

Market Cap	6.13M -42.6%
Revenue (ttm)	n/a
Net Income	-2.33M
EPS	-0.01
Shares Out	438.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	629,147
Open	0.0140
Previous Close	0.0140
Day's Range	0.0140 - 0.0160
52-Week Range	0.0140 - 0.0490
Beta	0.79
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 22, 2026

About Bio-Gene Technology

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BGT

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error